CRMD CorMedix Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CRMD

Price (delayed)

$7.69

Market cap

$599.39M

P/E Ratio

3.26

Dividend/share

N/A

EPS

$2.36

Enterprise value

$487.85M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 99

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its ...

Highlights
The EPS has surged by 195% year-on-year
CorMedix's equity has surged by 109% YoY and by 5% QoQ
The quick ratio has shrunk by 70% YoY and by 14% QoQ
The gross margin fell by 13% YoY and by 3.5% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cormedix.com
Peers: BDX EBS UTMD

Key stats

What are the main financial stats of CRMD

CRMD stock price

How has the CorMedix stock price performed over time
Intraday
-1.16%
1 week
-1.66%
1 month
-6.22%
1 year
-32.78%
YTD
-33.88%
QTD
-2.04%

Financial performance

How have CorMedix's revenue and profit performed over time
Revenue
$462.25M
Gross profit
$382.64M
Operating income
$217.04M
Net income
$187.17M
Gross margin
82.8%
Net margin
40.5%
CorMedix's operating margin has increased by 16% YoY but it has decreased by 2.9% QoQ
The revenue has grown by 16% from the previous quarter
The gross margin fell by 13% YoY and by 3.5% QoQ
The company's operating income rose by 12% QoQ

Price vs fundamentals

How does CRMD's price correlate with its fundamentals

Growth

What is CorMedix's growth rate over time

Valuation

What is CorMedix stock price valuation
CRMD P/E details
P/E
3.26
P/B
1.31
P/S
1.3
EV/EBIT
2.37
EV/EBITDA
2.02
EV/Sales
1.06
The EPS has surged by 195% year-on-year
The price to earnings (P/E) is 20% lower than the last 4 quarters average of 4.1
CorMedix's equity has surged by 109% YoY and by 5% QoQ
The P/B is 60% below the 5-year quarterly average of 3.3 and 27% below the last 4 quarters average of 1.8
The price to sales (P/S) is 100% lower than the 5-year quarterly average of 1355.5 and 45% lower than the last 4 quarters average of 2.4
The revenue has grown by 16% from the previous quarter

Efficiency

How efficient is CorMedix business performance
The ROA has contracted by 34% YoY and by 17% from the previous quarter
The company's return on invested capital fell by 33% YoY and by 7% QoQ
CorMedix's ROE has decreased by 12% from the previous quarter but it has increased by 4.4% YoY
The return on sales has declined by 4.9% since the previous quarter but it has increased by 4.7% year-on-year

Dividends

What is CRMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRMD.

Financial health

How did CorMedix financials performed over time
CRMD's total assets is 104% higher than its total liabilities
The quick ratio has shrunk by 70% YoY and by 14% QoQ
CRMD's current ratio has dropped by 67% year-on-year and by 14% since the previous quarter
The company's debt is 69% lower than its equity
CorMedix's equity has surged by 109% YoY and by 5% QoQ
CorMedix's debt to equity has decreased by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.